FDA Fast-Tracks Off-the-Shelf CAR-T for Aggressive T-Cell Cancers - Summary - MDSpire
Feature

FDA Fast-Tracks Off-the-Shelf CAR-T for Aggressive T-Cell Cancers

WashU Medicine-developed WU-CART-007 has received Breakthrough Therapy designation after early clinical results in relapsed or refractory T-cell leukemias and lymphomas.

  • April 14, 2026

  • 2 min

Share

Researchers at WashU Medicine have developed WU-CART-007 (soficabtagene geleucel), an off-the-shelf CAR-T cell therapy, which has received FDA Breakthrough Therapy designation for treating relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. This therapy aims to stabilize the disease sufficiently for patients to undergo stem cell transplantation, the only potential cure. Early clinical trials showed remarkable efficacy, with 10 out of 11 patients responding positively, highlighting the promising future of this treatment in oncology.

Original Source(s)

FDA Fast-Tracks Off-the-Shelf CAR-T for Aggressive T-Cell Cancers

  • April 14, 2026

Related Content

PSMA PET/CT Scan Reduces Need for Prostate Cancer Biopsies by 50%

A PSMA-11 PET/CT scan with gallium Ga-68 led to the identification of more aggressive prostate cancer cells in men with equivocal or nonsuspicious findings on multiparametric MRI than a standard biops...

Prompting Strategies May Improve Symptom Monitoring in Childhood Cancer Survivors

Prompting strategies on two large language models improved how the artificial intelligence (AI) interpreted pain and fatigue reported by survivors of childhood cancers for better symptom monitoring an...

Fluorine Tracking Offers Safer Alternative to Radioactive Drug Metabolism Studies

ICP-MS method enables early, quantitative metabolite analysis without radiolabels

  • April 14, 2026

  • 2 min